Generic patient self-report and investigator report instruments of therapeutic safety and tolerability

Journal of Rheumatology

Volumn 32, Issue 10, 2005, Pages 2033-2036

  Lassere, Marissa N D ^a,d   Johnson, Kent R ^b   Van Santen, Susanne ^c   Carlton, Kerri ^d   Rappo, Joy ^d   Michael, Rachel ^d   Kirwan, John R ^e   Edmonds, John P ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c Amsterdam Medical School   (Netherlands)

^d ST GEORGE HOSPITAL   (Australia)

^e BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Adverse event; Patient questionnaire; Randomized controlled trials

Indexed keywords

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; HUMAN; INSTRUMENT; METHODOLOGY; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SELF REPORT; STANDARDIZATION; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG TOXICITY; HEALTH STATUS; HUMANS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SELF DISCLOSURE;

EID: 26444598470     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. Lassere MND, Johnson KR, Woodworth T, et al. Challenges and progress in adverse event ascertainment and reporting in clinical trials. J Rheumatol 2005;32:2030-2.
2. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25:198-9.
3. Lassere MND, Johnson KR, Boers M, et al. Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 drug safety module update. J Rheumatol 2005;32:2037-41.
4. Woodworth TG, Furst DE, Strand V, et al. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: Towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. J Rheumatol 2001;28:1163-9.
5. Fries JF, Spitz PW, Williams CA, Bloch DA, Singh G, Hubert HB. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990;33:121-30.
6. Fries JF. ARAMIS and toxicity measurement (Arthritis Rheumatism and Aging Medical Information System). J Rheumatol 1995;22:995-7.
7. Fries JF. The hierarchy of quality-of-life assessment, the Health Assessment Questionnaire (HAQ), and issues mandating development of a toxicity index. Control Clin Trials 1991;12 Suppl:106S-17S.
8. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.